Company Overview
Vision and Mission
Leadership Team
Board of Directors
ESG
Contact Us
Pipeline and Major Products
Discovery
Manufacturing
Partners
Press Releases
Media Coverage
Awards
Presentations and Webcasts
Announcements and Circulars
Financial Reports and Listing Documents
Analyst Coverage
Corporate Governance
Events Calendar
IR Contact and Email Alert
Job Opportunities
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
Everest Medicines Announces the Departure of CEO, Kerry Blanchard
Everest Medicines Announces Interim Results for First Half of 2022
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy® in Asia Territories
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
Everest Medicines’ Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Everest Medicines’ Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
Everest Medicines Announces that Licensing Partner Gilead Sciences' Phase 3 TROPiCS-02 Study Meets Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer